The ABv+anti-PD-1 combination showed remarkable efficacy in a number of breast cancer models, which was somewhat surprising in light of the fact that BCL-2 dependency is most often observed in hematologic malignancies. The gene discussed is BCL2; the disease is breast carcinoma.